Diterpenes from European Euphorbia species serving as prototypes for natural-product-based drug discovery

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Diterpenes occurring in plants of the Euphorbiaceae family are of considerable interest in the context of natural product drug discovery programs because of their wide range of potentially valuable biological activities and their broad structural diversity due to their different polycyclic and macrocyclic skeletons and the various aliphatic and aromatic ester groups. Euphorbia species have provided many lead compounds (resiniferatoxin, prostratin, jatrophane and pepluane esters) for drug development, some of which are currently involved in preclinical or clinical studies, but the importance of natural products of this type can be demonstrated primarily by the recent approval of ingenol 3-angelate (ingenol mebutate) by the FDA for the treatment of actinic keratosis. An appreciable time has passed since a new plant chemotype - a natural product without structural modification - has been introduced into clinical practice. Ingenol 3-angelate, a Euphorbia peplus metabolite, serves as a new prototype for natural product-based drug discovery. The aim of this paper is to provide an overview of the chemical and pharmacological potential of European Euphorbia species. Besides the main aspects of the development of ingenol 3-angelate as a drug, screening methods, isolation strategies, the chemical characteristics of Euphorbia diterpenes and the results of pharmacological investigations are surveyed.

Original languageEnglish
Pages (from-to)5115-5130
Number of pages16
JournalEuropean Journal of Organic Chemistry
Issue number27
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Euphorbia
Diterpenes
Drug Discovery
Biological Products
drugs
prototypes
products
esters
Esters
Pharmacology
Euphorbiaceae
Lead compounds
Actinic Keratosis
lead compounds
Preclinical Drug Evaluations
metabolites
Metabolites
activity (biology)
Bioactivity
musculoskeletal system

Keywords

  • Antitumor agents
  • Euphorbiaceae
  • Macrocycles
  • Medicinal chemistry
  • Natural products
  • Terpenoids

ASJC Scopus subject areas

  • Organic Chemistry
  • Physical and Theoretical Chemistry

Cite this

@article{913d0fa0325a4ff69c4373fd03e8640f,
title = "Diterpenes from European Euphorbia species serving as prototypes for natural-product-based drug discovery",
abstract = "Diterpenes occurring in plants of the Euphorbiaceae family are of considerable interest in the context of natural product drug discovery programs because of their wide range of potentially valuable biological activities and their broad structural diversity due to their different polycyclic and macrocyclic skeletons and the various aliphatic and aromatic ester groups. Euphorbia species have provided many lead compounds (resiniferatoxin, prostratin, jatrophane and pepluane esters) for drug development, some of which are currently involved in preclinical or clinical studies, but the importance of natural products of this type can be demonstrated primarily by the recent approval of ingenol 3-angelate (ingenol mebutate) by the FDA for the treatment of actinic keratosis. An appreciable time has passed since a new plant chemotype - a natural product without structural modification - has been introduced into clinical practice. Ingenol 3-angelate, a Euphorbia peplus metabolite, serves as a new prototype for natural product-based drug discovery. The aim of this paper is to provide an overview of the chemical and pharmacological potential of European Euphorbia species. Besides the main aspects of the development of ingenol 3-angelate as a drug, screening methods, isolation strategies, the chemical characteristics of Euphorbia diterpenes and the results of pharmacological investigations are surveyed.",
keywords = "Antitumor agents, Euphorbiaceae, Macrocycles, Medicinal chemistry, Natural products, Terpenoids",
author = "A. Vasas and D. R{\'e}dei and Dezs{\"o} Csupor and J. Moln{\'a}r and J. Hohmann",
year = "2012",
month = "9",
doi = "10.1002/ejoc.201200733",
language = "English",
pages = "5115--5130",
journal = "LIEBIGS ANN. CHEM.",
issn = "1434-193X",
publisher = "Wiley-VCH Verlag",
number = "27",

}

TY - JOUR

T1 - Diterpenes from European Euphorbia species serving as prototypes for natural-product-based drug discovery

AU - Vasas, A.

AU - Rédei, D.

AU - Csupor, Dezsö

AU - Molnár, J.

AU - Hohmann, J.

PY - 2012/9

Y1 - 2012/9

N2 - Diterpenes occurring in plants of the Euphorbiaceae family are of considerable interest in the context of natural product drug discovery programs because of their wide range of potentially valuable biological activities and their broad structural diversity due to their different polycyclic and macrocyclic skeletons and the various aliphatic and aromatic ester groups. Euphorbia species have provided many lead compounds (resiniferatoxin, prostratin, jatrophane and pepluane esters) for drug development, some of which are currently involved in preclinical or clinical studies, but the importance of natural products of this type can be demonstrated primarily by the recent approval of ingenol 3-angelate (ingenol mebutate) by the FDA for the treatment of actinic keratosis. An appreciable time has passed since a new plant chemotype - a natural product without structural modification - has been introduced into clinical practice. Ingenol 3-angelate, a Euphorbia peplus metabolite, serves as a new prototype for natural product-based drug discovery. The aim of this paper is to provide an overview of the chemical and pharmacological potential of European Euphorbia species. Besides the main aspects of the development of ingenol 3-angelate as a drug, screening methods, isolation strategies, the chemical characteristics of Euphorbia diterpenes and the results of pharmacological investigations are surveyed.

AB - Diterpenes occurring in plants of the Euphorbiaceae family are of considerable interest in the context of natural product drug discovery programs because of their wide range of potentially valuable biological activities and their broad structural diversity due to their different polycyclic and macrocyclic skeletons and the various aliphatic and aromatic ester groups. Euphorbia species have provided many lead compounds (resiniferatoxin, prostratin, jatrophane and pepluane esters) for drug development, some of which are currently involved in preclinical or clinical studies, but the importance of natural products of this type can be demonstrated primarily by the recent approval of ingenol 3-angelate (ingenol mebutate) by the FDA for the treatment of actinic keratosis. An appreciable time has passed since a new plant chemotype - a natural product without structural modification - has been introduced into clinical practice. Ingenol 3-angelate, a Euphorbia peplus metabolite, serves as a new prototype for natural product-based drug discovery. The aim of this paper is to provide an overview of the chemical and pharmacological potential of European Euphorbia species. Besides the main aspects of the development of ingenol 3-angelate as a drug, screening methods, isolation strategies, the chemical characteristics of Euphorbia diterpenes and the results of pharmacological investigations are surveyed.

KW - Antitumor agents

KW - Euphorbiaceae

KW - Macrocycles

KW - Medicinal chemistry

KW - Natural products

KW - Terpenoids

UR - http://www.scopus.com/inward/record.url?scp=84866253543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866253543&partnerID=8YFLogxK

U2 - 10.1002/ejoc.201200733

DO - 10.1002/ejoc.201200733

M3 - Article

AN - SCOPUS:84866253543

SP - 5115

EP - 5130

JO - LIEBIGS ANN. CHEM.

JF - LIEBIGS ANN. CHEM.

SN - 1434-193X

IS - 27

ER -